Login to Your Account



Other News To Note


Tuesday, November 15, 2011
Dyax Corp., of Cambridge, Mass., said it has decided with partner Sigma-Tau Group, of Rome, to withdraw the European marketing authorization application for hereditary angioedema drug Kalbitor (ecallantide). Although Kalbitor is approved in the U.S., European regulators indicated the data were not sufficient to prove a positive risk-benefit.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription